Detection of unsuspected recurrent lymphoma with fluorodeoxyglucose- positron emission tomographic imaging after induction chemotherapy a case study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 2, 1998, Pages 126-128

  Alavi, Jane B ^a,b   Bénard, François ^b   Alavi, Abass ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fluorodeoxyglucose (FDG); Lymphoma; Positron emission tomography (PET)

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; TUMOR DIAGNOSIS;

ADULT; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, SMALL NONCLEAVED-CELL; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0345019837     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199804000-00005     Document Type: Article

References (22)

1. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074-8.
2. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987;22:360-71.
3. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988;150:189-97.
4. Coleman R. Multicenter prospective study of FDG-PET in the evaluation of indeterminate solitary pulmonary nodules (SPN) [Abstract]. J Nucl Med 1995;36:94P.
5. Rigo P, Paulus P, Kaschten B, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.
6. Karp J, Kinahan P, Muehllehnaer G. Effect of increased axial field of view on the performance of a volume PET scanner. IEEE Trans Med Imag 1993;12:299-306.
7. Smith R, Karp J, Muehllehner G, et al. Singles transmission scans performed post-injection for quantitative whole body PET imaging. IEEE Trans Nucl Sci 1997;44:1329-35.
8. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumours. Br J Cancer 1996;73:882-6.
9. Bangerter M, Kocher F, Binder T, et al. Total body positron emission tomography (PET) for staging and follow-up of lymphoma [Abstract]. Proc Am Soc Clin Oncol 1995;14:A1206.
10. Hoh C, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-8.
11. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522-7.
12. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-6.
13. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994;8:187-91.
14. Walsh RM, Wong WL, Chevretton EB, et al. The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphoma. Clin Oncol (R Coll Radiol) 1996;8:51-4.
15. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991;32:1211-8.
16. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988;29:1633-7.
17. Robert P. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-92.
18. Kubota K, Yamada K, Yoshioka S, et al. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992;17:361-3.
19. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-15.
20. Rodriguez M, Rehn S, Ahlstrom H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
21. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant mesothelioma. Ann Nucl Med 1994;8:187-91.
22. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-9.